



Retifanlimab

Revised: May 15, 2023.

CASRN: 2079108-44-2

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of retifanlimab during breastfeeding. Because retifanlimab is a large protein molecule with a molecular weight of 148,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] The manufacturer recommends avoiding breastfeeding during therapy and for 4 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. *Lancet Neurol.* 2023;22:350–66. PubMed PMID: 36931808.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Substance Identification

Substance Name

Retifanlimab

CAS Registry Number

2079108-44-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Antineoplastic Agents